• In January 2026, Trip.com Group disclosed that China’s State Administration for Market Regulation had opened an anti-monopoly investigation into the company, prompting multiple U.S. law firms such as Pomerantz LLP and Rosen Law Firm to examine potential securities-related claims on behalf of shareholders.
• At the same time, Trip.com Group reported strong Lunar New Year 2026 travel demand and advanced inbound tourism initiatives, underscoring a contrast between regulatory pressure and operational momentum in its core travel platforms.
• We will now examine how the Chinese antitrust probe and related shareholder investigations could influence Trip.com Group’s broader investment narrative.

AI is about to change healthcare. These 112 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Trip.com Group's Investment Narrative?

To own Trip.com Group, you need to be comfortable with a story that mixes solid travel demand, strong recent profitability and shareholder returns with an elevated layer of China-specific regulatory and legal risk. Before the January 2026 antitrust probe, the focus was on revenue growth, high margins, a low earnings multiple versus peers and ongoing dividends and buybacks as the key near term supports for the stock. The investigation by China’s State Administration for Market Regulation, and the sharp share price fall that triggered multiple U.S. law firm inquiries, now inserts regulatory outcomes as a central short term catalyst, alongside operating performance through peak travel periods. If penalties, business practice changes or reputational effects prove limited, the core thesis around cash generation and capital returns may remain largely intact.

However, investors should not ignore how a prolonged antitrust process could reshape Trip.com Group’s risk profile. Despite retreating, Trip.com Group's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$87 to US$125 per share, implying some holders see very large upside from current levels. Set against this, the fresh antitrust probe and related shareholder investigations highlight how regulatory outcomes could weigh on execution, which readers may want to factor alongside these community views when thinking about Trip.com Group’s future performance.

Explore 2 other fair value estimates on Trip.com Group - why the stock might be worth over 2x more than the current price!

Build Your Own Trip.com Group Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Trip.com Group research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Trip.com Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trip.com Group's overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.